Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and Type  2 diabetes

• Published in: Pharmacogenomics Vol. 8; no. 6; pp. 587 - 596
• Main Author: SSEda, OndøørrEj
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.06.2007
• Subjects: animal models; Animals; Anti-Obesity Agents - administration & dosage; Atherosclerosis; Development and progression; Diabetes Mellitus, Type 2 - genetics; Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - therapy; Drug Delivery Systems - methods; ecogenetics; Gene Targeting - methods; Genetic Variation - drug effects; Genetic Variation - genetics; glitazar; GW501516; Humans; metabolic syndrome; Obesity; Obesity - genetics; Obesity - metabolism; Obesity - therapy; Peroxisome Proliferator-Activated Receptors - agonists; Peroxisome Proliferator-Activated Receptors - genetics; Pharmacogenetics; pioglitazone; rosiglitazone; Type 2 diabetes; Type 2 diabetes

The three isotypes of peroxisome proliferator-activated receptors (PPARs) are currently perceived as major regulatory nodes (or hubs) of metabolic pathway networks, linking most prevalent diseases including Type  2 diabetes, obesity, dyslipidemia and atherosclerosis. The integrative functions of PPA...